Clinical Trial Update: High Dose Versus Routine Dose Icotinib in Advanced Non-small Cell Lung Cancer Patients With Stable Disease [Phase 2]

View source ↗

Summary

A Phase 2 clinical trial compares high-dose versus routine-dose icotinib in patients with advanced non-small cell lung cancer who have stable disease; the curre…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• icotinib (icotinib)

Snippet

Sponsor: Betta Pharmaceuticals Co., Ltd. | Conditions: Non-small Cell Lung Cancer | Phase 2 | Status: UNKNOWN